Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants
Despite being mutated in cancer and RASopathies, the role of the activation segment (AS) has not been addressed for B-Raf signaling in vivo. Here, we generated a conditional knock-in mouse allowing the expression of the B-RafAVKA mutant in which the AS phosphoacceptor sites T599 and S602 are replaced by alanine residues. Surprisingly, despite producing a kinase-impaired protein, the BrafAVKA allele does not phenocopy the lethality of Braf-knockout or paradoxically acting knock-in alleles. However, BrafAVKA mice display abnormalities in the hematopoietic system, a distinct facial morphology, reduced ERK pathway activity in the brain, and an abnormal gait. This phenotype suggests that maximum B-Raf activity is required for the proper development, function, and maintenance of certain cell populations. By establishing conditional murine embryonic fibroblast cultures, we further show that MEK/ERK phosphorylation and the immediate early gene response toward growth factors are impaired in the presence of B-RafAVKA. Importantly, alanine substitution of T599/S602 impairs the transformation potential of oncogenic non-V600E B-Raf mutants and a fusion protein, suggesting that blocking their phosphorylation could represent an alternative strategy to ATP-competitive inhibitors.
Source: EMBO Journal - Category: Molecular Biology Authors: Köhler, M., Röring, M., Schorch, B., Heilmann, K., Stickel, N., Fiala, G. J., Schmitt, L. C., Braun, S., Ehrenfeld, S., Uhl, F. M., Kaltenbacher, T., Weinberg, F., Herzog, S., Zeiser, R., Schamel, W. W., Jumaa, H., Brummer, T. Tags: Cancer, Signal Transduction Articles Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Genetics | Molecular Biology | Neurology